Newly vaccine strategy with mAbs against heat shock protein 90 (HSP90) on surface of antigen presenting cell (APC)
| Project/Area Number |
24700992
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor immunology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
SHUSAKU Mizukami 岡山大学, 医歯(薬)学総合研究科, 助教 (00508971)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 熱ショックタンパク質 / 抗体 / ワクチン / 抗原提示細胞 / アジュバント / モノクローナル抗体 / 細胞膜表面 / heat shock protein / クロスプレゼンテーション |
|---|
| Research Abstract |
Although HSP90 is a cytosolic molecular chaperone, our originally produced mAb 6H8 could detect cell surface HSP90 on APCs. As so far we reported, injection of 6H8 chemically conjugated with Ag (6H8-Ag) induced proliferation of adoptively transferred Ag specific CD8+T cells efficiently, compared with free Ag. Importantly those proliferation was dramatically enhanced by co-administration of free 6H8.
So I planned a project to confirm this phenomenon with solid tumor and human Ag model. But we found that 6H8's affinity was affected by Fc portion, due to it was an IgG2a Ab. Then, we prepared another cell surface HSP90 detectable IgG1 mAb and modified IgG1 type 6H8. Besides, we start immunization for Abs against STIP1 and HSC70, component of cell surface HSP complex in our hypothesis. Although, we couldn't carry out our original project enough so far, already mouse model for experiments with human Ag is available, so after finish the preparation of those Abs, we can restart our project.
|
Report
(3 results)
Research Products
(8 results)
